BBIBP-CorV inactivated vaccine is one of the most prevalent vaccines globally, but immune responses are far less studied than novel COVID-19 vaccine platforms. Longitudinal studies on BBIBP-CorV with homologous and heterologous booster doses are limited. This study follows a subset of participants from a national study comparing the immunogenicity of COVID-19 vaccines and levels of SARS-CoV-2 neutralising antibody (NAb). Homologous and heterologous booster dose significantly increased NAb levels in BBIBP-CorV-vaccinated individuals. Similar NAb levels were observed 1 month following BNT162b2 or mRNA-1273 booster. Interestingly, NAb persisted following mRNA-1273 booster (n = 95), but waned significantly at 6 and 9 months following BNT162b2 booster (n = 50; P > 0.001). The persistence of NAb was also observed following breakthrough infection. This study provides evidence that not all mRNA vaccines are equal in the longer term and should provide valuable information for policy makers planning booster programmes for BBIBP-CorV vaccinated populations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2023.10.044 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Heterologous prime-boost with mRNA-1273 stimulates persistent neutralising antibodies in BBIBP-CorV-vaccinated individuals.
Vaccine
November 2023
PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei Darussalam.
BBIBP-CorV inactivated vaccine is one of the most prevalent vaccines globally, but immune responses are far less studied than novel COVID-19 vaccine platforms. Longitudinal studies on BBIBP-CorV with homologous and heterologous booster doses are limited. This study follows a subset of participants from a national study comparing the immunogenicity of COVID-19 vaccines and levels of SARS-CoV-2 neutralising antibody (NAb).
View Article and Find Full Text PDFNeutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
Genome Med
December 2022
State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Background: The emergence of SARS-CoV-2 Omicron subvariants has raised questions regarding resistance to immunity by natural infection or immunization. We examined the sensitivity of Delta and Omicron subvariants (BA.1, BA.
View Article and Find Full Text PDFComparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm.
Iran J Immunol
September 2022
Department of Physiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
Article Synopsis
- The study compares the antibody response of healthy individuals vaccinated with either the AstraZeneca or Sinopharm COVID-19 vaccines, focusing on those with no prior infection.
- It involved 37 participants, with 17 receiving the AstraZeneca vaccine and 20 the Sinopharm vaccine, whose antibody levels were measured four weeks after each dose using ELISA.
- Results showed significantly higher levels of neutralizing antibodies and anti-receptor-binding domain IgG in AstraZeneca recipients compared to Sinopharm, indicating a potential need for booster doses in Sinopharm recipients to enhance their immune response.
Article Synopsis
- - The effectiveness of the BBIBP-CorV COVID-19 vaccine is low in populations that received two doses, prompting interest in alternative vaccination strategies.
- - A study at Makassed General Hospital tested the safety and effectiveness of a BNT162b2 booster dose for individuals who had completed the BBIBP-CorV regimen, finding higher antibody levels and good tolerability with heterologous vaccination.
- - Mixing the BBIBP-CorV and BNT162b2 vaccines shows promise for enhancing immunity in areas lacking access to mRNA vaccines, potentially offering better protection against new variants.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!